Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast in MCI and Early Alzheimer's Disease
NCT03991988Phase 2Completed
- Sponsor
- Emory University
- Start
- Sep 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) comparing Montelukast Group with Placebo Group (2 arms). Primary endpoints: Number of Participants With Any Gastrointestinal (GI) Symptoms at 1 year, Number of Participants With Reported Anaphylaxis at 1 year and 5 more. Started Sep 2019; status: completed.
02
Drugs
montelukast
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03991988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991988.